Private equity meets China biotech: PAG infuses $540M to gain control of Hisun's biosimilar subsidiary

Private equity firm PAG has emerged as the winner in a bidding war for Hisun BioRay, the biotech unit of Chinese generics and API maker …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pri­vate eq­ui­ty meets Chi­na biotech: PAG in­fus­es $540M to gain con­trol of Hisun's biosim­i­lar sub­sidiary